Market Overview

UPDATE: Jefferies Raises PT on Celldex Therapeutics on Encouraging Pipeline Outlook


In a report published Friday, Jefferies reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and raised its price target from $9.00 to $15.00.

Jefferies noted, “CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously).”

Celldex Therapeutics closed on Thursday at $10.49.

Latest Ratings for CLDX

Feb 2021HC Wainwright & Co.MaintainsBuy
Oct 2020HC Wainwright & Co.MaintainsBuy
Mar 2020H.C. WainwrightReiteratesBuy

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings


Related Articles (CLDX)

View Comments and Join the Discussion!

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

Latest Ratings

BKNGCredit SuisseMaintains2,640.0
XECMKM PartnersDowngrades60.0
NSCEvercore ISI GroupDowngrades
COLBPiper SandlerDowngrades47.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at